Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).
Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).
The programmes will evaluate ST-601 as a therapy for the treatment of anterior uveitis and ST-603 as a potential therapy for dry eye syndrome.
The addition of these two Phase III studies brings the number of Sirion's active clinical programmes to five.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.